Maury Raycroft
Stock Analyst at Jefferies
(1.42)
# 3,617
Out of 5,113 analysts
57
Total ratings
34.88%
Success rate
-8.26%
Average return
Main Sectors:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $114 → $63 | $24.44 | +157.77% | 1 | Dec 30, 2025 | |
| MREO Mereo BioPharma Group | Downgrades: Hold | $7 → $0.5 | $0.45 | +11.36% | 2 | Dec 30, 2025 | |
| CELC Celcuity | Maintains: Buy | $108 → $134 | $114.53 | +17.00% | 2 | Dec 2, 2025 | |
| AUPH Aurinia Pharmaceuticals | Upgrades: Buy | $10 → $21 | $14.57 | +44.13% | 1 | Nov 7, 2025 | |
| OPK OPKO Health | Downgrades: Hold | $2 → $1.6 | $1.28 | +25.00% | 1 | Oct 31, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $550 → $549 | $349.58 | +57.05% | 4 | Oct 30, 2025 | |
| KZR Kezar Life Sciences | Downgrades: Hold | $18 → $7 | $6.15 | +13.82% | 2 | Oct 17, 2025 | |
| KOD Kodiak Sciences | Initiates: Buy | $15 | $26.07 | -42.46% | 1 | Sep 22, 2025 | |
| CRDF Cardiff Oncology | Initiates: Hold | $3.5 | $1.62 | +116.05% | 1 | Jun 24, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $8.70 | +509.20% | 2 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $8 | $6.16 | +29.87% | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $3 | $0.36 | +724.40% | 1 | Dec 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $10.13 | -40.77% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $11.18 | +69.95% | 1 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $23 → $15 | $4.03 | +272.21% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $39 | $50.50 | -22.77% | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.37 | +1,517.25% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.60 | +1,337.50% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $2.79 | +6,889.25% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $6.66 | +65.17% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $45.11 | -86.70% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $65.58 | +14.36% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $3.38 | +225.44% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $31.08 | -13.13% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $1.55 | +222.58% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $9.42 | +282.17% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $6.55 | +1,503.05% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $53.69 | +220.36% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $2.57 | +1,728.79% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $13.82 | +203.91% | 3 | Nov 1, 2017 |
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Buy
Price Target: $114 → $63
Current: $24.44
Upside: +157.77%
Mereo BioPharma Group
Dec 30, 2025
Downgrades: Hold
Price Target: $7 → $0.5
Current: $0.45
Upside: +11.36%
Celcuity
Dec 2, 2025
Maintains: Buy
Price Target: $108 → $134
Current: $114.53
Upside: +17.00%
Aurinia Pharmaceuticals
Nov 7, 2025
Upgrades: Buy
Price Target: $10 → $21
Current: $14.57
Upside: +44.13%
OPKO Health
Oct 31, 2025
Downgrades: Hold
Price Target: $2 → $1.6
Current: $1.28
Upside: +25.00%
Alnylam Pharmaceuticals
Oct 30, 2025
Maintains: Buy
Price Target: $550 → $549
Current: $349.58
Upside: +57.05%
Kezar Life Sciences
Oct 17, 2025
Downgrades: Hold
Price Target: $18 → $7
Current: $6.15
Upside: +13.82%
Kodiak Sciences
Sep 22, 2025
Initiates: Buy
Price Target: $15
Current: $26.07
Upside: -42.46%
Cardiff Oncology
Jun 24, 2025
Initiates: Hold
Price Target: $3.5
Current: $1.62
Upside: +116.05%
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $8.70
Upside: +509.20%
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $6.16
Upside: +29.87%
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.36
Upside: +724.40%
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $10.13
Upside: -40.77%
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $11.18
Upside: +69.95%
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $4.03
Upside: +272.21%
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $50.50
Upside: -22.77%
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.37
Upside: +1,517.25%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $1.60
Upside: +1,337.50%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $2.79
Upside: +6,889.25%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $6.66
Upside: +65.17%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $45.11
Upside: -86.70%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $65.58
Upside: +14.36%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $3.38
Upside: +225.44%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $31.08
Upside: -13.13%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $1.55
Upside: +222.58%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $9.42
Upside: +282.17%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $6.55
Upside: +1,503.05%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $53.69
Upside: +220.36%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $2.57
Upside: +1,728.79%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $13.82
Upside: +203.91%